<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mary A Albrecht, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Martin S Hirsch, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer Mitty, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 16, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genital herpes simplex virus (HSV) infections are a major global public health problem:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A dramatic upsurge in genital HSV infections has been documented from seroprevalence studies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is a wide diversity of the clinical spectrum of genital HSV disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Like all herpes virus strains, HSV establishes a latent state followed by viral reactivation and recurrent local disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perinatal transmission of HSV can lead to significant fetal morbidity and mortality.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A link has been established between HSV-related genital ulcer disease and sexual transmission of HIV.
        </p>
        <p>
        </p>
        <p>
         The epidemiology, varied clinical manifestations, and diagnosis of genital HSV infection will be reviewed here. The treatment of this disorder and issues related to genital herpes in pregnancy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8346.html" rel="external">
          "Treatment of genital herpes simplex virus infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8344.html" rel="external">
          "Prevention of genital herpes virus infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8340.html" rel="external">
          "Genital herpes simplex virus infection and pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) are common infections worldwide. Both HSV-1 and HSV-2 can cause genital herpes, and infection of the same anatomic site by both HSV-1 and HSV-2 has been documented [
         <a href="#rid1">
          1
         </a>
         ]. However, genital HSV is frequently under-recognized because infection is often subclinical [
         <a href="#rid2">
          2-4
         </a>
         ].
        </p>
        <p>
         Most cases of recurrent genital herpes are caused by HSV-2 [
         <a href="#rid5">
          5,6
         </a>
         ]. From 2005 to 2010, the seroprevalence of HSV-2 in the United States was approximately 16 percent among patients aged 14 to 49 [
         <a href="#rid7">
          7
         </a>
         ]. In one study that evaluated 7293 patients in this age group, the seroprevalence increased with age and number of sexual partners, and was greater among women compared with men (21 versus 12 percent) [
         <a href="#rid8">
          8
         </a>
         ]. HSV-2 seroprevalence was also three times greater among non-Hispanic Black patients (39 percent) than among non-Hispanic White patients (12 percent). Similar risk factors for HSV-2 positivity have been noted in other surveys [
         <a href="#rid3">
          3,9-13
         </a>
         ]. Prior HSV-1 infection does not appear to affect the rate of HSV-2 acquisition [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         However, HSV-1 has been associated with an increasing proportion of cases of genital herpes infection, especially among young women and men who have sex with men [
         <a href="#rid3">
          3,5,15-17
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Over a two-year follow-up of 1427 HIV-seronegative MSM in Australia, incidence rates for HSV-1 and HSV-2 infection were 5.9 and 1.5 cases per 100 person-years, respectively [
         <a href="#rid17">
          17
         </a>
         ]. In a multivariate analysis, incident infection with HSV-1 was significantly associated with younger age and reports of insertive oral sex with casual partners.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective analysis of genital herpes isolates from a university student health service in the United States, HSV-1 was more commonly isolated in women than men, and the proportion of newly diagnosed HSV-1 genital infection had increased from 31 percent in 1993 to 78 percent in 2001 [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among 3438 HSV-seronegative women between the ages of 18 and 30 in the United States and Canada who were enrolled in the control arm of a herpes vaccine study and who were followed prospectively between 2003 and 2007, 183 became infected with HSV: 127 (3.7 percent) with HSV-1 and 56 (1.6 percent) with HSV-2 [
         <a href="#rid3">
          3
         </a>
         ]. The rate of infection for HSV-1 was more than twice the rate for HSV-2 (2.5 versus 1.1 per 100 person-years, respectively). HSV-1 was more common than HSV-2 as a cause of genital mucosal infections.
        </p>
        <p>
        </p>
        <p>
         It is estimated that the majority of genital herpes infections are transmitted by persons unaware that they have the infection, or are asymptomatic when transmission occurs [
         <a href="#rid6">
          6
         </a>
         ]. As an example, in a population-based cross-sectional survey of adults living in New York City, nearly 28 percent were infected with HSV-2 and 88 percent had no prior knowledge of their diagnosis [
         <a href="#rid4">
          4
         </a>
         ]. In addition, prior HSV-1 infection increases the likelihood of asymptomatic HSV-2 infection by threefold [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          TYPES OF INFECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical designations of genital herpes simplex virus (HSV) infection are: primary, nonprimary first episode, and recurrent  (
         <a class="graphic graphic_table graphicRef80693" href="/z/d/graphic/80693.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Primary
         </span>
         <span class="headingEndMark">
          —
         </span>
         Primary infection refers to infection in a patient without preexisting antibodies to either herpes simplex virus type 1 (HSV-1) or herpes simplex virus type 2 (HSV-2).
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Nonprimary
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonprimary first episode infection refers to the acquisition of genital HSV-1 in a patient with preexisting antibodies to HSV-2 or the acquisition of genital HSV-2 in a patient with preexisting antibodies to HSV-1 (eg, an individual with prior orolabial herpes and subsequent development of an HSV-1 antibody response develops genital herpes due to HSV-2 exposure).
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Recurrent
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recurrent infection refers to reactivation of genital HSV in which the HSV type recovered in the lesion is the same type as antibodies in the serum.
        </p>
        <p>
         Each of these types can be either symptomatic or asymptomatic (also called subclinical). Asymptomatic infection will be detected only if the patient is tested by culture or polymerase chain reaction (PCR).
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          TRANSMISSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transmission of herpes simplex virus (HSV) may occur quickly in new sexual relationships. In a prospective study of 199 patients with newly acquired HSV genital infection, the median duration of the sexual relationship was 3.5 months (range 1.5 to 10 months) and the median number of sex acts before transmission was 40 [
         <a href="#rid18">
          18
         </a>
         ]. Condom use was infrequent (50 percent during first intercourse; 20 percent during last intercourse before diagnosis). The median time to infection was greater in participants whose partners informed them that they had genital herpes than in those whose partners did not (270 versus 60 days).
        </p>
        <p>
         Transmission may also occur during periods of subclinical viral shedding (eg, when symptoms are absent). (See
         <a class="local">
          'Viral shedding'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical manifestations of genital herpes simplex virus (HSV) vary widely depending upon whether the infection is primary, nonprimary or recurrent.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Primary infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The average incubation period for developing genital herpes after an exposure is four days (range 2 to 12 days) [
         <a href="#rid19">
          19
         </a>
         ]. The clinical manifestations of primary genital HSV infection are highly variable [
         <a href="#rid19">
          19,20
         </a>
         ]. The initial presentation can be severe with painful genital ulcers, dysuria, fever, tender local inguinal lymphadenopathy  (
         <a class="graphic graphic_picture graphicRef122030 graphicRef122031" href="/z/d/graphic/122030.html" rel="external">
          picture 1A-B
         </a>
         ), and headache. In other patients, however, the infection is mild, subclinical, or entirely asymptomatic [
         <a href="#rid12">
          12,20
         </a>
         ]. There are no clear differences in clinical presentation based on infecting virus (ie, HSV-1 versus HSV-2) [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The characteristic skin lesions of HSV infection begin as grouped 2 to 4 mm vesicles with associated underlying erythema that progress to vesicopustules, erosions, and ulcerations. Vesicles and pustules may exhibit a central depression, referred to as an "umbilicated" appearance. Erosions and ulcerations often have scalloped borders.
        </p>
        <p>
         In one review, patients with primary infections usually had multiple, bilateral, ulcerating, pustular lesions which resolved after a mean of 19 days [
         <a href="#rid20">
          20
         </a>
         ]. Symptoms tended to be more severe in women than in men. Other symptoms and signs in these first episode infections included:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systemic symptoms, including fever, headache, malaise, and myalgias (67 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Local pain and itching (98 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dysuria (63 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tender lymphadenopathy (80 percent)
        </p>
        <p>
        </p>
        <p>
         The clinician should differentiate dysuria from acute urinary retention, which can occur during severe primary HSV infection. Dysuria can lead to reluctance to void because of the passage of acidic urine on open and inflamed vesicles; this is best managed with Sitz baths. However, acute urinary retention with loss of sacral sensation can occur due to lumbosacral radiculomyelitis secondary to severe primary HSV infection. (See
         <a class="local">
          'Sacral radiculitis'
         </a>
         below.)
        </p>
        <p>
         Primary genital herpes is commonly associated with viremia; of 164 adults with confirmed primary genital HSV infection, 40 (24 percent) had HSV DNA detected in plasma [
         <a href="#rid21">
          21
         </a>
         ]. In one study, virus was isolated most commonly from the urethra and cervix of women with first episode infection (82 and 88 percent, respectively) [
         <a href="#rid20">
          20
         </a>
         ]. Viral isolation was less frequent from the urethra in men (28 percent) and the pharynx in either women or men (13 and 7 percent, respectively).
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Nonprimary infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonprimary first episode infection is associated with fewer lesions and less systemic symptoms than primary infection, presumably because antibodies against one HSV type offer some protection against the other [
         <a href="#rid19">
          19,20
         </a>
         ]. In one study, prior HSV-1 infection increased the likelihood of asymptomatic infection three-fold [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Recurrent infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical recurrences of genital HSV are common, but are typically less severe than primary or nonprimary infections  (
         <a class="graphic graphic_picture graphicRef122025 graphicRef58485 graphicRef122026 graphicRef122027" href="/z/d/graphic/122025.html" rel="external">
          picture 2A-D
         </a>
         ). The mean duration of lesions is generally shorter with recurrences than in primary infection (10 versus 19 days) and the duration of viral shedding is usually two to five days [
         <a href="#rid12">
          12,20,22
         </a>
         ].
        </p>
        <p>
         In one study that included a subset of 362 patients with recurrent infection, lesions were described as unilateral small vesicular or ulcerative lesions [
         <a href="#rid20">
          20
         </a>
         ]. Atypical vaginal lesions include fissures or vulvar irritation. Systemic symptoms are infrequent and approximately 25 percent of recurrent episodes are completely asymptomatic [
         <a href="#rid20">
          20
         </a>
         ]. As many as 50 percent of patients with symptomatic recurrences have prodromal symptoms before eruption such as local mild tingling or shooting pains in the buttocks, legs, and hips [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         Factors that contribute to decreased recurrences include infection with HSV-1 compared to HSV-2 and the duration and severity of the primary infection [
         <a href="#rid12">
          12
         </a>
         ]. Treatment with
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         does not influence recurrence rates [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          EXTRAGENITAL COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Extragenital manifestations (eg, radiculitis, aseptic meningitis, urinary retention) typically occur during the primary episode of herpes simplex virus (HSV) infection, but they can recur with subsequent episodes.
        </p>
        <p class="headingAnchor" id="H851926419">
         <span class="h2">
          Neurologic
         </span>
         <span class="headingEndMark">
          —
         </span>
         Extragenital complications occur in a minority of patients who present with primary herpes simplex virus (HSV) infection. In one study, extragenital complications included aseptic meningitis (8 percent) and urinary bladder retention due to sacral autonomic nervous system dysfunction (2 percent), [
         <a href="#rid20">
          20
         </a>
         ]. Other series have noted higher rates of aseptic meningitis (25 percent) and urinary retention syndromes (10 to 15 percent) in women with primary infection [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Meningitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with HSV meningitis, the cerebrospinal fluid (CSF) profile includes a pleocytosis (median white cell count 300 to 400/mm
         <sup>
          3
         </sup>
         ) with a predominance of lymphocytes, and a normal CSF glucose concentration, although hypoglycorrhachia has been reported [
         <a href="#rid20">
          20
         </a>
         ]. HSV has been isolated from 0.5 to 3 percent of CSF samples from patients with aseptic meningitis. (See
         <a class="medical medical_review" href="/z/d/html/1296.html" rel="external">
          "Aseptic meningitis in adults"
         </a>
         .)
        </p>
        <p>
         HSV-2 can also cause recurrent episodes of meningitis, called Mollaret's meningitis. Most patients do not have evidence of genital lesions at the time of presentation. (See
         <a class="medical medical_review" href="/z/d/html/1296.html" rel="external">
          "Aseptic meningitis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2430530699">
         <span class="h3">
          Sacral radiculitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute urinary retention with loss of sacral sensation can occur due to lumbosacral radiculitis secondary to severe primary HSV infection [
         <a href="#rid23">
          23
         </a>
         ]. This complication is transient but usually requires catheterization until clinical improvement ensues. In a series of 30 patients who developed acute lumbosacral radiculitis featuring cauda equina syndrome with myelitis (referred to as Elsberg syndrome), urinary retention was present in 77 percent, and half had lower extremity weakness [
         <a href="#rid24">
          24
         </a>
         ]. Neurologic manifestations in immunocompromised patients are discussed below. (See
         <a class="local">
          'Immunosuppressed patients'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Proctitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         HSV can also cause proctitis, particularly in men who have sex with men (MSM). The differential diagnosis of proctitis in MSM includes N. gonorrhoeae, herpes simplex virus, and Treponema pallidum infections. The frequency of these causes was evaluated in a review of 101 episodes of proctitis among MSM in San Francisco; anoscopy was performed and specimens obtained that were tested for the above organisms [
         <a href="#rid25">
          25
         </a>
         ]. The following etiologies were noted in 55 percent of cases with a confirmed diagnosis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gonorrhea (20 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Herpes simplex (13 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chlamydia (11 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mixed infections (10 percent, including 3 percent with herpes)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Syphilis (1 percent)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          FREQUENCY OF RECURRENCES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with primary genital herpes simplex virus (HSV) need to be counseled that recurrence is expected. The frequency of recurrence depends on the severity and duration of the initial episode, the infecting serotype, and the host.
        </p>
        <p>
         In one series of 457 patients with HSV-2 primary infection, 89 percent had one recurrence during a follow-up of 391 days [
         <a href="#rid2">
          2
         </a>
         ]. Furthermore, 38 percent of patients had as many as six recurrences and 20 percent had more than ten. Patients with primary infection lasting for five or more weeks experienced recurrences earlier and almost twice as often compared to those with a shorter duration of the initial infection.
        </p>
        <p>
         Recurrent infection is more common with HSV-2 than HSV-1 [
         <a href="#rid22">
          22,26
         </a>
         ]. The magnitude of this effect was evaluated in a prospective study of 137 patients with a first symptomatic episode of genital herpes [
         <a href="#rid26">
          26
         </a>
         ]. The likelihood of recurrence was much higher with HSV-2 infections (60 versus 14 percent with HSV-1). As a result, the proportion of episodes due to HSV-1 fell from 15 percent in primary first episodes to 2 percent in recurrent episodes.
        </p>
        <p>
         Recurrences are also more common in immunosuppressed patients. (See
         <a class="local">
          'Immunosuppressed patients'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          VIRAL SHEDDING
         </span>
         <span class="headingEndMark">
          —
         </span>
         After resolution of the primary genital herpes simplex virus (HSV) infection, asymptomatic intermittent viral shedding occurs in both men and women, even in the absence of genital lesions [
         <a href="#rid13">
          13,27-30
         </a>
         ]. A prospective study of 498 immunocompetent HSV-2-seropositive persons demonstrated that HSV was shed more frequently in the 410 symptomatic persons compared with the 88 asymptomatic persons (20 percent versus 10 percent of days), although the quantities of virus were similar between the two groups [
         <a href="#rid30">
          30
         </a>
         ]. HSV genital shedding can also occur during a clinical outbreak primarily affecting the buttock region, which may reflect reactivation from sacral neural ganglia [
         <a href="#rid31">
          31
         </a>
         ]. Subclinical HSV shedding is important since infection can be transmitted unknowingly to susceptible sexual partners and neonates. (See
         <a class="local">
          'Sex partners'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/8340.html" rel="external">
          "Genital herpes simplex virus infection and pregnancy"
         </a>
         .)
        </p>
        <p>
         The frequency of shedding is influenced by the infecting serotype, whether the infection is primary or nonprimary and the duration of time since the first clinical episode.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Primary genital HSV-2 infections have been linked to more frequent and prolonged asymptomatic viral shedding from the genitourinary tract compared to HSV-1 infections [
         <a href="#rid15">
          15,22,26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one study of 110 women with a median follow-up period of 105 days, viral shedding occurred on a mean of two percent of days, most often within seven days of a symptomatic recurrence, and was more likely to occur in patients with HSV-2 or mixed HSV-1 and HSV-2 infections compared to HSV-1 alone (55 and 52 versus 29 percent of patients) [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A lower frequency of subclinical infection was noted in a cohort study of 306 women with a first episode of genital HSV infection [
         <a href="#rid32">
          32
         </a>
         ]. Asymptomatic viral shedding was detected among 18, 23, and 12 percent of women with primary HSV-2, nonprimary HSV-2, and primary HSV-1 genital infections, respectively. Asymptomatic cervical viral shedding was three times more frequent during the first three months following resolution of primary HSV-2 disease than at later time points and was consistently more common in patients with HSV-2 compared to HSV-1 genital infections.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Time since the first genital HSV episode was significantly associated with reduced genital shedding in a study of 377 adults who self-collected anogenital swabs for HSV-2 DNA for a minimum of 30 consecutive days [
         <a href="#rid33">
          33
         </a>
         ]. The frequency of subclinical HSV shedding occurred in 26 percent of days among patients infected less than one year to 9 percent of days among those infected for more than 10 years. Although the frequency of subclinical shedding decreased, the quantity of virus remained stable over time, which may be associated with continued risk for transmission.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          SEX PARTNERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several studies have evaluated the risk of sexual transmission of genital herpes from index patients with recurrent herpes simplex virus (HSV) genital disease to susceptible partners [
         <a href="#rid34">
          34,35
         </a>
         ]. In one report, 144 heterosexual couples, in which the source partner had symptomatic recurrent genital HSV, were evaluated over a median of 334 days for development of culture-confirmed HSV infection or type-specific antibodies in the susceptible partner [
         <a href="#rid34">
          34
         </a>
         ]. The following findings were noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transmission of genital HSV was documented in 14 couples (10 percent); the risk was greater with male than with female source partners (17 versus 4 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In susceptible women who lacked HSV-1 and HSV-2 antibodies at entry, the rate of acquiring genital herpes infections was higher than in women with preexisting HSV-1 antibodies (32 versus 9 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In 70 percent of patients, transmission of genital herpes was linked to sexual contact during periods of asymptomatic viral shedding. (See
         <a class="local">
          'Viral shedding'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         A second smaller study supported these findings of a greater risk of HSV acquisition with male source partners [
         <a href="#rid35">
          35
         </a>
         ]. However, studies have demonstrated discordant findings regarding the risk of acquiring HSV-2 in patients with prior HSV-1 infection [
         <a href="#rid35">
          35,36
         </a>
         ].
        </p>
        <p>
         A more detailed discussion of how to prevent transmission of HSV to sex partners is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8287.html" rel="external">
          "Treatment and prevention of herpes simplex virus type 1 in immunocompetent adolescents and adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          IMMUNOSUPPRESSED PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most genital herpes simplex virus (HSV) infections occurring in immunosuppressed adults reflect reactivation syndromes. The clinical presentation of symptomatic episodes may include extensive mucocutaneous involvement, variable appearance of genital lesions, and the development of chronic and recurrent ulcers  (
         <a class="graphic graphic_picture graphicRef122032 graphicRef122033" href="/z/d/graphic/122032.html" rel="external">
          picture 3A-B
         </a>
         ). Recurrences are often more frequent, more extensive, and of longer duration than in immunocompetent patients [
         <a href="#rid37">
          37,38
         </a>
         ]. In addition, immunosuppressed patients may have prolonged viral shedding.
        </p>
        <p>
         A prospective trial evaluated 217 HIV-infected women who underwent twice yearly pelvic examination, including cultures of cervicovaginal specimens and swab specimens from genital lesions, if lesions were present [
         <a href="#rid39">
          39
         </a>
         ]. The following findings were noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One-third had genital HSV-2 infection based upon history alone or positive culture results.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among these women, an HSV-2 culture was positive in one-third of visits; a positive culture was not associated with an apparent genital lesion approximately one-third of the time.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Positive cultures occurred more frequently in patients with lower CD4 cell counts and higher plasma HIV-1 RNA levels. However, in one study, even optimum CD4 gains and viral suppression with ART did not eliminate the risk of significantly more genital lesions in HIV-infected women compared to controls [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In addition to genital symptoms, neurologic complications occasionally develop and rapidly evolve in the setting of genital and mucocutaneous HSV infection occurring in transplant recipients and in HIV-infected patients with advanced disease. These complications include aseptic meningitis, sacral radiculopathy, and transverse myelitis [
         <a href="#rid41">
          41-43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          PREGNANCY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genital herpes simplex virus (HSV) infection is of particular concern in pregnant women because of the risk of transmission to the infant during delivery. This issue is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8340.html" rel="external">
          "Genital herpes simplex virus infection and pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          HSV-2 AND RISK OF HIV TRANSMISSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Herpes simplex virus type 2 (HSV-2) genital ulcer disease has been definitively linked to an increased risk for acquisition of HIV-1 infection in regions with high seroprevalence rates of HSV-2 infection [
         <a href="#rid44">
          44-54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Epidemiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         A 2002 meta-analysis of 31 studies was undertaken to assess the risk of acquiring HIV infection in HSV-2 seropositive individuals [
         <a href="#rid47">
          47
         </a>
         ]. Depending upon the type of study, the risk estimate in HSV-2 seropositive individuals varied from 2.1 (95% CI 1.4-3.2) to 3.9 (95% CI 3.1-5.1). However, the temporal sequence of the two infections could not be determined.
        </p>
        <p>
         In a subsequent meta-analysis, 18 longitudinal studies were selected in which the relative timing of HSV-2 and HIV infections could be determined [
         <a href="#rid55">
          55
         </a>
         ]. This study demonstrated that prevalent HSV-2 infection was associated with a three-fold increased risk of HIV acquisition among both men and women in the general population. Modeling studies also demonstrate that HSV-2 epidemics could theoretically double the peak HIV incidence and create a "core group" of HIV transmitters in areas where HSV is highly prevalent [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         Subsequent studies have underscored the relative importance of recent HSV infection, as compared to remote HSV infection, as a risk factor for HIV acquisition [
         <a href="#rid46">
          46,52,56
         </a>
         ]. In a pivotal seroepidemiologic study conducted in India, a cohort of 2732 HIV-seronegative patients (17 percent female) followed at sexually transmitted disease (STD) and reproductive tract clinics underwent HSV-2 antibody screening at baseline and were prospectively followed to assess for seroconversion to HIV-1 and HSV-2 [
         <a href="#rid46">
          46
         </a>
         ]. The prevalence of HSV-2 at the time of enrollment was 43 percent, almost one-half of whom reported no history of genital ulcer disease. The following findings were noted during follow-up:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The incidence of HSV-2 and HIV infection was 11.4 cases and 5.8 cases/100 person-years, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The risk of acquiring HIV infection in this cohort was 3.6 percent for HSV-2 seronegative individuals at baseline, 7.5 percent for individuals with positive HSV-2 serology at baseline, and 22.6 percent for individuals with confirmed recent HSV-2 seroconversion within the past 6 months. The adjusted hazard ratios for HIV infection were 1.67 for HSV-2 infection at study entry, 1.92 for remote incident HSV-2 infection, and 3.81 for recent incident HSV-2 infection.
        </p>
        <p>
        </p>
        <p>
         This association between HIV acquisition and HSV infection, particularly recent HSV infection, was confirmed in a nested case-control study in Tanzanian patients attending STD clinics [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         These findings underscore the need for effective HSV-2 interventions when implementing infection control strategies designed to limit HIV transmission. Clinical trials evaluating the impact of antiviral treatment of HSV-2 infected individuals with
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         or
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         on the incidence of HIV sexual transmission may provide pivotal information about how to implement interventional therapies on a global scale [
         <a href="#rid51">
          51,53,57
         </a>
         ]. There is also promising data on the use of an intravaginal gel that has antiviral activity against both HIV and HSV [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Mechanisms
         </span>
         <span class="headingEndMark">
          —
         </span>
         At least three mechanisms may be important for the increase in HIV-1 transmission associated with sexual activity in patients with HSV-2 infection:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptomatic HSV-2 genital ulcers frequently cause local inflammation and mucosal disruption in the genital tract, which can facilitate HIV-1 entry during exposure to HIV-infected genital fluids [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Genital HSV-2 ulcers selectively increase local recruitment of CD4 positive cells, which may serve as targets for HIV-1 attachment in mucosal tissue [
         <a href="#rid59">
          59,60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Replication competent virus has been isolated in HSV-2 lesions [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients with genital herpes who present with a genital ulcer, the primary differential diagnosis includes syphilis and chancroid among infectious causes, and drug eruptions and Behçet’s syndrome among noninfectious causes. (See
         <a class="medical medical_review" href="/z/d/html/7592.html" rel="external">
          "Approach to the patient with genital ulcers"
         </a>
         .)
        </p>
        <p>
         A diagnosis based upon history and physical examination alone is often inaccurate. Therefore, the clinical diagnosis of genital herpes should be confirmed by laboratory testing. Nonetheless, some findings are more common in certain infections [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The classic presentation of genital herpes is with multiple, shallow, tender ulcers that may be vesicular; in addition, only herpes simplex virus (HSV) is associated with recurrent disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The classic genital presentation of primary syphilis is with a painless, indurated, clean-based ulcer, called a chancre.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The classic genital presentation of chancroid is with a deep, undermined, purulent ulcer that may be associated with painful inguinal lymphadenitis. (See
         <a class="medical medical_review" href="/z/d/html/7582.html" rel="external">
          "Chancroid"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A clinical diagnosis of genital herpes should be confirmed with laboratory testing [
         <a href="#rid62">
          62
         </a>
         ]. The classical presentation with multiple vesicles on an erythematous base is often absent in many patients. Thus, it is important to confirm the diagnosis of herpes simplex virus (HSV) infection with either of the following techniques: viral culture, polymerase chain reaction (PCR), direct fluorescence antibody, and type-specific serologic tests. The choice of test varies with the clinical presentation [
         <a href="#rid62">
          62
         </a>
         ]. PCR-based testing and cell culture are the preferred tests for a patient presenting with active lesions, although PCR-based testing has the greatest overall sensitivity and specificity.
        </p>
        <p class="headingAnchor" id="H602473165">
         <span class="h2">
          Virologic tests
         </span>
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h3">
          Polymerase chain reaction
         </span>
         <span class="headingEndMark">
          —
         </span>
         While viral culture has remained the standard diagnostic method for isolating HSV, real-time HSV PCR assays have emerged as a more sensitive method to confirm HSV infection in clinical specimens obtained from genital ulcers and mucocutaneous sites; PCR is the test of choice for cerebrospinal fluid [
         <a href="#rid6">
          6,63-66
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8286.html" rel="external">
          "PCR testing for the diagnosis of herpes simplex virus in patients with encephalitis or meningitis"
         </a>
         .)
        </p>
        <p>
         The enhanced sensitivity of HSV PCR compared to viral culture can be illustrated by the following observations from different studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HSV DNA levels with PCR testing were 250 times higher from culture-positive compared to culture-negative samples [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among women with recurrent genital herpes who underwent daily sampling of genital lesions, HSV DNA was detected in ulcerative lesions on 15 of 17 days compared to only 3 of 17 days by viral isolation [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A randomized trial compared
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         ,
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         , and placebo for suppression of HSV shedding in the genital tract [
         <a href="#rid69">
          69
         </a>
         ]. During the placebo period, both the lesional HSV shedding rate (87 versus 47 percent of days) and the asymptomatic shedding rate (27 versus 7 percent of days) were significantly higher with PCR than with culture. The higher sensitivity of PCR compared to culture was also confirmed in the treatment phase of the study.
        </p>
        <p>
        </p>
        <p>
         Earlier diagnosis by real-time HSV PCR assays may also reduce the transmission of infection during reactivation syndromes that are manifested only by asymptomatic viral shedding [
         <a href="#rid67">
          67,70,71
         </a>
         ]. In clinical studies, PCR testing has been used to evaluate the risk of transmission in discordant couples and the effectiveness of suppression with antiviral therapy [
         <a href="#rid68">
          68,69
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8346.html" rel="external">
          "Treatment of genital herpes simplex virus infection"
         </a>
         .)
        </p>
        <p>
         Further development of this assay now allows differentiation of HSV-1 and HSV-2 using real-time TaqMan PCR techniques [
         <a href="#rid72">
          72
         </a>
         ]. A limiting factor in adopting real-time HSV PCR as the primary diagnostic tool in many clinical reference laboratories is the cost of the assay, which substantially exceeds that of viral culture.
        </p>
        <p class="headingAnchor" id="H560831622">
         <span class="h3">
          Viral culture
         </span>
         <span class="headingEndMark">
          —
         </span>
         If active genital lesions are present, the vesicle should be unroofed for sampling of vesicular fluid for culture. However, the overall sensitivity of viral culture of genital lesions is only approximately 50 percent [
         <a href="#rid70">
          70,73
         </a>
         ]. The diagnostic yield of culture is highest in the early stages of disease, when lesions are typically vesicular, and declines rapidly as the lesions begin to heal [
         <a href="#rid71">
          71
         </a>
         ]. Viral isolation rates are also higher with primary compared to recurrent genital herpes, particularly in the setting of asymptomatic recurrences with subclinical shedding.
        </p>
        <p>
         Specimens for culture should be directly placed in viral culture media and rapidly transported to the laboratory. Viral isolates usually grow in tissue culture by five days and are typed by antibody staining.
        </p>
        <p class="headingAnchor" id="H1801546">
         <span class="h3">
          Direct fluorescent antibody
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many diagnostic laboratories provide a rapid type-specific direct fluorescent antibody (DFA) test to detect HSV in clinical specimens. This test is specific and reproducible.
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h2">
          Serologic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several FDA-approved type-specific HSV serologic tests are commercially available to clinicians evaluating genital ulcer disease in adults [
         <a href="#rid74">
          74-76
         </a>
         ]. Type-specific antibodies to HSV develop during the first several weeks after infection and persist indefinitely [
         <a href="#rid6">
          6
         </a>
         ]. Most serologic tests are laboratory-based glycoprotein G type-specific tests, although rapid tests are also available and can be completed in 15 minutes at the point of care [
         <a href="#rid77">
          77
         </a>
         ]. The availability of type-specific serology using surface glycoproteins (gG2 and gG1 for HSV-2 and HSV-1, respectively) to distinguish HSV-1 and HSV-2 enables the clinician to determine if the patient is at risk of acquisition or has evidence of prior infection with either subtype [
         <a href="#rid28">
          28,78
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          When to consider serologic testing
         </strong>
         – In patients with genital ulcer disease, serologic testing can be used to support the diagnosis of HSV infection in certain settings [
         <a href="#rid6">
          6,74,75
         </a>
         ]. These include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A patient with a history of genital lesions who did not have a diagnostic workup or had a negative HSV culture or PCR.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A patient with an atypical presentation. In some patients (eg, those with atypical vaginal/genital burning pain, dysesthesias), the use of PCR testing in addition to serology may be helpful. (See
         <a class="local">
          'Polymerase chain reaction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         HSV IgM testing is not type specific and is generally not recommended since is not useful for differentiating oral versus genital infection or discriminating primary versus recurrent episodes of HSV infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The use of serologic testing for screening asymptomatic patients (eg, during pregnancy, determining susceptibility of a sexual partner of a patient with documented genital HSV infection) is discussed below. (See
         <a class="local">
          'Screening'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interpretation
         </strong>
         – Positive serologic testing for HSV-2 typically indicates anogenital infection, whereas positive serologic testing for HSV-1 can be consistent with either anogenital or orolabial infection. However, since genital ulcers have many possible etiologies, a positive HSV IgG antibody alone cannot be used to confirm a diagnosis of HSV. Confirmation of HSV in a patient with an active genital ulcer requires further diagnostic evaluation, such as PCR or culture. (See
         <a class="local">
          'Virologic tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, there are several limitations to serologic testing. As an example, the sensitivities of glycoprotein G type-specific tests for detecting HSV-2 antibody vary from 80 to 98 percent, and false negative results may occur at early stages of infection [
         <a href="#rid6">
          6
         </a>
         ]. In cases of recent suspected HSV-2 acquisition, repeat type-specific antibody testing can be performed 12 weeks after the presumed time of acquisition. In addition, a positive culture or PCR test for HSV in an HSV-seronegative patient is strong evidence of primary infection [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         False-positive HSV-2 test results can also occur; this is frequently seen at low index values (1.1 to 3) with the most commonly used test, HerpeSelect HSV-2 enzyme immunoassay (EIA) [
         <a href="#rid6">
          6,79
         </a>
         ]. In the setting of low index values, a confirmatory test (Biokit or Western blot) with a second method should be performed, particularly if testing was ordered in someone at low-risk for genital HSV. If confirmatory tests are unavailable, patients should be counseled about the limitations of available testing before obtaining serologic tests.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h2">
          Tzanck smear
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Tzanck smear, which may demonstrate the cytopathic effect of the virus (multinucleate giant cells), can be performed on lesion scrapings from patients with active genital lesions  (
         <a class="graphic graphic_picture graphicRef79784" href="/z/d/graphic/79784.html" rel="external">
          picture 4
         </a>
         ). However, it has limited utility since it has low sensitivity and specificity and is only helpful if positive [
         <a href="#rid80">
          80
         </a>
         ]. Furthermore, only a viral culture or PCR-based testing can determine whether the infection is due to HSV-1 or HSV-2. A description of how to do the Tzanck smear is found in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/5562.html" rel="external">
          "Office-based dermatologic diagnostic procedures", section on 'Tzanck smear'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H32">
         <span class="h1">
          SCREENING
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach for most patients
         </strong>
         – Routine serologic screening for herpes simplex virus-1 or 2 (HSV-1 or HSV-2) is
         <strong>
          not
         </strong>
         recommended in most asymptomatic adolescents and adults. This approach is supported by the US Preventive Services Task Force [
         <a href="#rid81">
          81
         </a>
         ]. Although there is a theoretical benefit of serologic screening given the relatively high seroprevalence rate of HSV-2, and the increase in genital herpes due to HSV-1, there are significant limitations of serologic testing. As examples:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Available HSV-2 serologic tests have a low specificity and a high false-positive rate when used for screening asymptomatic individuals, and confirmatory testing is not widely available. In a systematic review that included 10 studies, the sensitivity and specificity of the most commonly used tests were estimated to be 99 and 81 percent, respectively; assuming the prevalence of HSV-2 is 16 percent, the positive predictive value would be 50 percent [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serologic tests for HSV-1 cannot differentiate oral from genital infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Given these limitations, and the lack of specific treatment interventions for asymptomatic individuals, the anxiety and disruption of personal relationships that can be associated with a positive test result outweigh the potential benefits of screening. More detailed information on the limitations of serologic testing is discussed above. (See
         <a class="local">
          'Serologic testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Considerations in select populations
         </strong>
         – Screening should be performed to identify asymptomatic HSV infection in pregnant persons, since those with HSV infection are at risk for shedding at the time of delivery with potential transmission to the infant. (See
         <a class="medical medical_review" href="/z/d/html/8340.html" rel="external">
          "Genital herpes simplex virus infection and pregnancy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, serologic screening is useful for determining susceptibility to HSV in individuals who have a partner with genital herpes. The role of antiviral therapy to reduce the risk of transmission to uninfected partners is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/8344.html" rel="external">
          "Prevention of genital herpes virus infections", section on 'Determining partner susceptibility to infection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H294031138">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111582.html" rel="external">
          "Society guideline links: Sexually transmitted infections"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H33">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15442.html" rel="external">
          "Patient education: Genital herpes (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/4006.html" rel="external">
          "Patient education: Genital herpes (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H34">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Herpes simplex virus (HSV) is a common sexually transmitted disease worldwide. Although HSV-2 has historically been the main causative agent for virologically confirmed genital infections, HSV-1 is associated with an increasing proportion of cases of genital herpes. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transmission
         </strong>
         – Transmission of HSV may occur quickly in new sexual relationships. Among susceptible sexual partners, there is a greater risk of HSV acquisition when the source is male. (See
         <a class="local">
          'Sex partners'
         </a>
         above and
         <a class="local">
          'Transmission'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         After resolution of the primary genital HSV infection, asymptomatic intermittent viral shedding has been documented in both men and women in the absence of genital lesions. Subclinical HSV shedding is important since infection can be transmitted unknowingly to susceptible sexual partners and neonates. (See
         <a class="local">
          'Viral shedding'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Types of infection
         </strong>
         – The clinical designations of genital HSV infection are: primary, nonprimary first episode, and recurrent infection. Primary infection refers to infection in a patient without preexisting antibodies to either HSV-1 or HSV-2. Nonprimary first episode infection refers to the acquisition of genital HSV in a patient with preexisting antibodies to the alternate serotype. Recurrent infection refers to reactivation of genital HSV in which the HSV type recovered in the lesion is the same type as those seen on serologic testing. (See
         <a class="local">
          'Types of infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – The clinical manifestations of primary genital HSV infection are highly variable. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initial infection
         </strong>
         – In some patients, the initial presentation can be severe with painful genital ulcers and constitutional symptoms  (
         <a class="graphic graphic_picture graphicRef122030 graphicRef122031" href="/z/d/graphic/122030.html" rel="external">
          picture 1A-B
         </a>
         ), in others, the infection may be mild or entirely asymptomatic. Nonprimary first episode infection is associated with fewer lesions and less systemic symptoms than primary infection, presumably because antibodies against one HSV type offer some protection against the other. (See
         <a class="local">
          'Nonprimary infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Recurrent infection
         </strong>
         – Clinical recurrences of genital HSV are common, but are typically less severe than the initial infection  (
         <a class="graphic graphic_picture graphicRef122026 graphicRef122025 graphicRef58485 graphicRef122027" href="/z/d/graphic/122026.html" rel="external">
          picture 2A-D
         </a>
         ). The frequency of recurrences depends on the severity and duration of the initial episode, the infecting serotype, and the host. As an example, in immunosuppressed patients, symptomatic episodes may more severe, frequent, and longer in duration  (
         <a class="graphic graphic_picture graphicRef122032 graphicRef122033" href="/z/d/graphic/122032.html" rel="external">
          picture 3A-B
         </a>
         ). (See
         <a class="local">
          'Recurrent infection'
         </a>
         above and
         <a class="local">
          'Immunosuppressed patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Extragenital complications
         </strong>
         – Extragenital complications (eg, aseptic meningitis and urinary retention) occur in a minority of patients, and typically present in those with primary HSV infection. (See
         <a class="local">
          'Extragenital complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – For those with evidence of infection, the diagnosis of HSV is best confirmed through polymerase chain reaction (PCR) testing of a sample obtained from an active genital lesion. Viral culture can also be used to confirm the diagnosis, but it is less sensitive than PCR. For patients without an active lesion at the time of presentation, serologic testing can be performed to support the diagnosis. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Screening
         </strong>
         – For most asymptomatic adolescents and adults, routine serologic screening for HSV-1 or HSV-2 is
         <strong>
          not
         </strong>
         indicated. Exceptions include persons who are pregnant and those with an unknown HSV status if they have a partner with genital herpes. (See
         <a class="local">
          'Screening'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Sucato G, Wald A, Wakabayashi E, et al. Evidence of latency and reactivation of both herpes simplex virus (HSV)-1 and HSV-2 in the genital region. J Infect Dis 1998; 177:1069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994; 121:847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein DI, Bellamy AR, Hook EW 3rd, et al. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis 2013; 56:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schillinger JA, McKinney CM, Garg R, et al. Seroprevalence of herpes simplex virus type 2 and characteristics associated with undiagnosed infection: New York City, 2004. Sex Transm Dis 2008; 35:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296:964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradley H, Markowitz LE, Gibson T, McQuillan GM. Seroprevalence of herpes simplex virus types 1 and 2--United States, 1999-2010. J Infect Dis 2014; 209:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years--United States, 2005-2008. MMWR Morb Mortal Wkly Rep 2010; 59:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cowan FM, Johnson AM, Ashley R, et al. Relationship between antibodies to herpes simplex virus (HSV) and symptoms of HSV infection. J Infect Dis 1996; 174:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nahmias AJ, Lee FK, Beckman-Nahmias S. Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl 1990; 69:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arvin AM, Prober CG. Herpes simplex virus type 2--a persistent problem. N Engl J Med 1997; 337:1158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis 1998; 26:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sizemore JM Jr, Lakeman F, Whitley R, et al. The spectrum of genital herpes simplex virus infection in men attending a sexually transmitted disease clinic. J Infect Dis 2006; 193:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langenberg AG, Corey L, Ashley RL, et al. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 1999; 341:1432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross JD, Smith IW, Elton RA. The epidemiology of herpes simplex types 1 and 2 infection of the genital tract in Edinburgh 1978-1991. Genitourin Med 1993; 69:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis 2003; 30:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jin F, Prestage GP, Mao L, et al. Transmission of herpes simplex virus types 1 and 2 in a prospective cohort of HIV-negative gay men: the health in men study. J Infect Dis 2006; 194:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wald A, Krantz E, Selke S, et al. Knowledge of partners' genital herpes protects against herpes simplex virus type 2 acquisition. J Infect Dis 2006; 194:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimberlin DW, Rouse DJ. Clinical practice. Genital herpes. N Engl J Med 2004; 350:1970.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 1983; 98:958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnston C, Magaret A, Selke S, et al. Herpes simplex virus viremia during primary genital infection. J Infect Dis 2008; 198:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wald A, Zeh J, Selke S, et al. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995; 333:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eberhardt O, Küker W, Dichgans J, Weller M. HSV-2 sacral radiculitis (Elsberg syndrome). Neurology 2004; 63:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savoldi F, Kaufmann TJ, Flanagan EP, et al. Elsberg syndrome: A rarely recognized cause of cauda equina syndrome and lower thoracic myelitis. Neurol Neuroimmunol Neuroinflamm 2017; 4:e355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klausner JD, Kohn R, Kent C. Etiology of clinical proctitis among men who have sex with men. Clin Infect Dis 2004; 38:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reeves WC, Corey L, Adams HG, et al. Risk of recurrence after first episodes of genital herpes. Relation to HSV type and antibody response. N Engl J Med 1981; 305:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342:844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koutsky LA, Stevens CE, Holmes KK, et al. Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. N Engl J Med 1992; 326:1533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mark KE, Wald A, Magaret AS, et al. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis 2008; 198:1141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tronstein E, Johnston C, Huang ML, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA 2011; 305:1441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerkering K, Gardella C, Selke S, et al. Isolation of herpes simplex virus from the genital tract during symptomatic recurrence on the buttocks. Obstet Gynecol 2006; 108:947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koelle DM, Benedetti J, Langenberg A, Corey L. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med 1992; 116:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phipps W, Saracino M, Magaret A, et al. Persistent genital herpes simplex virus-2 shedding years following the first clinical episode. J Infect Dis 2011; 203:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mertz GJ, Benedetti J, Ashley R, et al. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992; 116:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bryson Y, Dillon M, Bernstein DI, et al. Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study. J Infect Dis 1993; 167:942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu F, Schillinger JA, Sternberg MR, et al. Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994. J Infect Dis 2002; 185:1019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foley E, Patel R. Treatment of genital herpes infections in HIV-infected patients. J HIV Ther 2004; 9:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Severson JL, Tyring SK. Relation between herpes simplex viruses and human immunodeficiency virus infections. Arch Dermatol 1999; 135:1393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright PW, Hoesley CJ, Squires KE, et al. A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: correlations with CD4 cell count and plasma HIV-1 RNA level. Clin Infect Dis 2003; 36:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ameli N, Bacchetti P, Morrow RA, et al. Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations. AIDS 2006; 20:1051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Momméja-Marin H, Lafaurie M, Scieux C, et al. Herpes simplex virus type 2 as a cause of severe meningitis in immunocompromised adults. Clin Infect Dis 2003; 37:1527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corral I, Quereda C, Navas E, et al. Sacral myeloradiculitis complicating genital herpes in a HIV-infected patient. Int J STD AIDS 2005; 16:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoritaka A, Ohta K, Kishida S. Herpetic lumbosacral radiculoneuropathy in patients with human immunodeficiency virus infection. Eur Neurol 2005; 53:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schacker T, Ryncarz AJ, Goddard J, et al. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998; 280:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Telzak EE, Chiasson MA, Bevier PJ, et al. HIV-1 seroconversion in patients with and without genital ulcer disease. A prospective study. Ann Intern Med 1993; 119:1181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynolds SJ, Risbud AR, Shepherd ME, et al. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J Infect Dis 2003; 187:1513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002; 185:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krone MR, Wald A, Tabet SR, et al. Herpes simplex virus type 2 shedding in human immunodeficiency virus-negative men who have sex with men: frequency, patterns, and risk factors. Clin Infect Dis 2000; 30:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schacker T, Zeh J, Hu HL, et al. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis 1998; 178:1616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mbopi-Kéou FX, Grésenguet G, Mayaud P, et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis 2000; 182:1090.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blower S, Ma L. Calculating the contribution of herpes simplex virus type 2 epidemics to increasing HIV incidence: treatment implications. Clin Infect Dis 2004; 39 Suppl 5:S240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Todd J, Grosskurth H, Changalucha J, et al. Risk factors influencing HIV infection incidence in a rural African population: a nested case-control study. J Infect Dis 2006; 193:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartlett JG. Recent developments in the management of herpes simplex virus infection in HIV-infected persons. Clin Infect Dis 2004; 39 Suppl 5:S237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berger JR, Houff S. Neurological complications of herpes simplex virus type 2 infection. Arch Neurol 2008; 65:596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kapiga SH, Sam NE, Bang H, et al. The role of herpes simplex virus type 2 and other genital infections in the acquisition of HIV-1 among high-risk women in northern Tanzania. J Infect Dis 2007; 195:1260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Celum CL, Robinson NJ, Cohen MS. Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection. J Infect Dis 2005; 191 Suppl 1:S107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keller MJ, Zerhouni-Layachi B, Cheshenko N, et al. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. J Infect Dis 2006; 193:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koelle DM, Abbo H, Peck A, et al. Direct recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions. J Infect Dis 1994; 169:956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rebbapragada A, Wachihi C, Pettengell C, et al. Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS 2007; 21:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiCarlo RP, Martin DH. The clinical diagnosis of genital ulcer disease in men. Clin Infect Dis 1997; 25:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta R, Warren T, Wald A. Genital herpes. Lancet 2007; 370:2127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramaswamy M, McDonald C, Smith M, et al. Diagnosis of genital herpes by real time PCR in routine clinical practice. Sex Transm Infect 2004; 80:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Filén F, Strand A, Allard A, et al. Duplex real-time polymerase chain reaction assay for detection and quantification of herpes simplex virus type 1 and herpes simplex virus type 2 in genital and cutaneous lesions. Sex Transm Dis 2004; 31:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimberlin DW, Lakeman FD, Arvin AM, et al. Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1996; 174:1162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strick LB, Wald A. Diagnostics for herpes simplex virus: is PCR the new gold standard? Mol Diagn Ther 2006; 10:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cone RW, Hobson AC, Brown Z, et al. Frequent detection of genital herpes simplex virus DNA by polymerase chain reaction among pregnant women. JAMA 1994; 272:792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cone RW, Hobson AC, Palmer J, et al. Extended duration of herpes simplex virus DNA in genital lesions detected by the polymerase chain reaction. J Infect Dis 1991; 164:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta R, Wald A, Krantz E, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis 2004; 190:1374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schomogyi M, Wald A, Corey L. Herpes simplex virus-2 infection. An emerging disease? Infect Dis Clin North Am 1998; 12:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moseley RC, Corey L, Benjamin D, et al. Comparison of viral isolation, direct immunofluorescence, and indirect immunoperoxidase techniques for detection of genital herpes simplex virus infection. J Clin Microbiol 1981; 13:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corey L, Huang ML, Selke S, Wald A. Differentiation of herpes simplex virus types 1 and 2 in clinical samples by a real-time taqman PCR assay. J Med Virol 2005; 76:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lafferty WE, Coombs RW, Benedetti J, et al. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med 1987; 316:1444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashley RL. Sorting out the new HSV type specific antibody tests. Sex Transm Infect 2001; 77:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wald A, Ashley-Morrow R. Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin Infect Dis 2002; 35:S173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prince HE, Ernst CE, Hogrefe WR. Evaluation of an enzyme immunoassay system for measuring herpes simplex virus (HSV) type 1-specific and HSV type 2-specific IgG antibodies. J Clin Lab Anal 2000; 14:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashley-Morrow R, Nollkamper J, Robinson NJ, et al. Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. Clin Microbiol Infect 2004; 10:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whittington WL, Celum CL, Cent A, Ashley RL. Use of a glycoprotein G-based type-specific assay to detect antibodies to herpes simplex virus type 2 among persons attending sexually transmitted disease clinics. Sex Transm Dis 2001; 28:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feltner C, Grodensky C, Ebel C, et al. Serologic Screening for Genital Herpes: An Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2016; 316:2531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sen P, Barton SE. Genital herpes and its management. BMJ 2007; 334:1048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           US Preventive Services Task Force, Mangione CM, Barry MJ, et al. Serologic Screening for Genital Herpes Infection: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA 2023; 329:502.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 8347 Version 30.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9534984" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Evidence of latency and reactivation of both herpes simplex virus (HSV)-1 and HSV-2 in the genital region.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7978697" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Recurrence rates in genital herpes after symptomatic first-episode infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23087395" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18418295" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Seroprevalence of herpes simplex virus type 2 and characteristics associated with undiagnosed infection: New York City, 2004.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16926356" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Sexually Transmitted Infections Treatment Guidelines, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24136792" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Seroprevalence of herpes simplex virus types 1 and 2--United States, 1999-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20414188" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years--United States, 2005-2008.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8769602" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Relationship between antibodies to herpes simplex virus (HSV) and symptoms of HSV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2175939" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9329938" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Herpes simplex virus type 2--a persistent problem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9524821" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Herpes simplex viruses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16518750" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The spectrum of genital herpes simplex virus infection in men attending a sexually transmitted disease clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10547406" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8244358" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The epidemiology of herpes simplex types 1 and 2 infection of the genital tract in Edinburgh 1978-1991.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14520181" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16897652" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Transmission of herpes simplex virus types 1 and 2 in a prospective cohort of HIV-negative gay men: the health in men study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16741881" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Knowledge of partners' genital herpes protects against herpes simplex virus type 2 acquisition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15128897" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Clinical practice. Genital herpes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6344712" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Genital herpes simplex virus infections: clinical manifestations, course, and complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18471083" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Herpes simplex virus viremia during primary genital infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7643884" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Virologic characteristics of subclinical and symptomatic genital herpes infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15326269" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : HSV-2 sacral radiculitis (Elsberg syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28534040" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Elsberg syndrome: A rarely recognized cause of cauda equina syndrome and lower thoracic myelitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14699467" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Etiology of clinical proctitis among men who have sex with men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6264300" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Risk of recurrence after first episodes of genital herpes. Relation to HSV type and antibody response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10727588" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1315930" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Underdiagnosis of genital herpes by current clinical and viral-isolation procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18783315" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21486977" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17012458" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Isolation of herpes simplex virus from the genital tract during symptomatic recurrence on the buttocks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1310837" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21288817" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Persistent genital herpes simplex virus-2 shedding years following the first clinical episode.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1309413" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Risk factors for the sexual transmission of genital herpes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8383724" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11930310" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15071425" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Treatment of genital herpes infections in HIV-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10566840" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Relation between herpes simplex viruses and human immunodeficiency virus infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12522754" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: correlations with CD4 cell count and plasma HIV-1 RNA level.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16603858" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14614676" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Herpes simplex virus type 2 as a cause of severe meningitis in immunocompromised adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15807949" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Sacral myeloradiculitis complicating genital herpes in a HIV-infected patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15942245" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Herpetic lumbosacral radiculoneuropathy in patients with human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9660365" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8239249" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : HIV-1 seroconversion in patients with and without genital ulcer disease. A prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12721931" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11756980" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10671325" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Herpes simplex virus type 2 shedding in human immunodeficiency virus-negative men who have sex with men: frequency, patterns, and risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9815213" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10979904" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15494895" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Calculating the contribution of herpes simplex virus type 2 epidemics to increasing HIV incidence: treatment implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16388496" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Risk factors influencing HIV infection incidence in a rural African population: a nested case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15494894" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Recent developments in the management of herpes simplex virus infection in HIV-infected persons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18474734" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Neurological complications of herpes simplex virus type 2 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16327322" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17396994" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The role of herpes simplex virus type 2 and other genital infections in the acquisition of HIV-1 among high-risk women in northern Tanzania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15627220" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16323128" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8169426" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Direct recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17314521" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9332527" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : The clinical diagnosis of genital ulcer disease in men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18156035" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Genital herpes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15459412" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Diagnosis of genital herpes by real time PCR in routine clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15167640" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Duplex real-time polymerase chain reaction assay for detection and quantification of herpes simplex virus type 1 and herpes simplex virus type 2 in genital and cutaneous lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8940204" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16646574" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Diagnostics for herpes simplex virus: is PCR the new gold standard?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8078144" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Frequent detection of genital herpes simplex virus DNA by polymerase chain reaction among pregnant women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1654360" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Extended duration of herpes simplex virus DNA in genital lesions detected by the polymerase chain reaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15378428" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9494829" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Herpes simplex virus-2 infection. An emerging disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6263945" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Comparison of viral isolation, direct immunofluorescence, and indirect immunoperoxidase techniques for detection of genital herpes simplex virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15902702" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Differentiation of herpes simplex virus types 1 and 2 in clinical samples by a real-time taqman PCR assay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3033506" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11463920" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Sorting out the new HSV type specific antibody tests.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12353203" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10645979" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Evaluation of an enzyme immunoassay system for measuring herpes simplex virus (HSV) type 1-specific and HSV type 2-specific IgG antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15191381" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11234793" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Use of a glycoprotein G-based type-specific assay to detect antibodies to herpes simplex virus type 2 among persons attending sexually transmitted disease clinics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27997660" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Serologic Screening for Genital Herpes: An Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17510153" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Genital herpes and its management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36786784" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Serologic Screening for Genital Herpes Infection: US Preventive Services Task Force Reaffirmation Recommendation Statement.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
